Background: Direct oral anticoagulants (DOACs) are suitable for some patients with cerebral venous thrombosis (CVT). The optimal transition strategy from parenteral anticoagulation (PA) to DOAC is not known. We examined duration of PA prior to DOAC initiation and outcomes in ACTION-CVT, an international retrospective study. Methods: We compared three groups: no lead-in PA, 1-4 days (d) of PA, and 5-21d of PA. The primary outcome at day 90 (D90) was a composite of CVT recurrence/extension and symptomatic intracranial hemorrhage (sICH). Secondary outcomes (D90) were complete venous recanalization and mRS of 0-2. We evaluated outcomes using descriptive statistics and crude and adjusted logistic regression modeling. Results: Of 231 patients treated with DOAC, 11.7% had no lead-in PA, 64.5% 1-4d, 23.8% 5-21d. Compared to those with <5d, those with 5-21d had worse clinical-radiological presentations at baseline, including more focal deficits, encephalopathy, and ICH (Table 1). Primary outcome events were low overall; all 6 occurred in the <5d group. Odds of complete recanalization were lower in the <5d group, although this difference attenuated with adjustment for baseline characteristics. There were no differences in odds of mRS 0-2. (Table 2) Conclusions: Individuals treated with DOAC for CVT who received 5-21d of PA had more severe clinical and radiological presentations compared to those with <5d. Rates of CVT extension, recurrence and sICH were too low to reach conclusions regarding safety of one strategy over another. Odds of complete recanalization were higher in those with 5-21d PA, but these differences attenuated after adjustment for baseline patient characteristics.
Read full abstract